Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUC 7483 BS dose-ranging study in overactive bladder
2004-004590-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ritobegron in overactive bladder (OAB) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline to week 8 in average number of micturitions per 24 hours. Started Feb 2005; status: completed.
02
Drugs
ritobegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2004-004590-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004590-28.